Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

669 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nonclinical Efficacy and Safety of CX-2029, an Anti-CD71 Probody-Drug Conjugate.
Singh S, Serwer L, DuPage A, Elkins K, Chauhan N, Ravn M, Buchanan F, Wang L, Krimm M, Wong K, Sagert J, Tipton K, Moore SJ, Huang Y, Jang A, Ureno E, Miller A, Patrick S, Duvur S, Liu S, Vasiljeva O, Li Y, Henriques T, Badagnani I, Jeffries S, Schleyer S, Leanna R, Krebber C, Viswanathan S, Desnoyers L, Terrett J, Belvin M, Morgan-Lappe S, Kavanaugh WM, Richardson J. Singh S, et al. Among authors: viswanathan s. Mol Cancer Ther. 2022 Aug 2;21(8):1326-1336. doi: 10.1158/1535-7163.MCT-21-0193. Mol Cancer Ther. 2022. PMID: 35666803 Free PMC article.
The Effect of ASP2409, a Novel CD86-Selective Variant of CTLA4-Ig, on Renal Allograft Rejection in Nonhuman Primates.
Oshima S, Karrer EE, Kawato Y, Maeda M, Fukahori H, Tsujimoto S, Hirose J, Nakamura K, Marui T, Takamura F, Noto T, Chapin SJ, Fujii Y, Neighbors M, Viswanathan S, Devens BH, Higashi Y. Oshima S, et al. Among authors: viswanathan s. Transplantation. 2016 Dec;100(12):2611-2620. doi: 10.1097/TP.0000000000001397. Transplantation. 2016. PMID: 27861289
ASP2408 and ASP2409, novel CTLA4-Ig variants with CD86-selective ligand binding activity and improved immunosuppressive potency, created by directed evolution.
Oshima S, Karrer EE, Paidhungat MM, Neighbors M, Chapin SJ, Fan RA, Reed MA, Wu K, Wong C, Chen Y, Whitlow M, Anderson FA, Bam RA, Zhang Q, Larsen BR, Viswanathan S, Devens BH, Bass SH, Higashi Y. Oshima S, et al. Among authors: viswanathan s. Protein Eng Des Sel. 2016 May;29(5):159-67. doi: 10.1093/protein/gzw002. Epub 2016 Mar 10. Protein Eng Des Sel. 2016. PMID: 26968452
Directed evolution of gene-shuffled IFN-alpha molecules with activity profiles tailored for treatment of chronic viral diseases.
Brideau-Andersen AD, Huang X, Sun SC, Chen TT, Stark D, Sas IJ, Zadik L, Dawes GN, Guptill DR, McCord R, Govindarajan S, Roy A, Yang S, Gao J, Chen YH, Skartved NJ, Pedersen AK, Lin D, Locher CP, Rebbapragada I, Jensen AD, Bass SH, Nissen TL, Viswanathan S, Foster GR, Symons JA, Patten PA. Brideau-Andersen AD, et al. Among authors: viswanathan s. Proc Natl Acad Sci U S A. 2007 May 15;104(20):8269-74. doi: 10.1073/pnas.0609001104. Epub 2007 May 9. Proc Natl Acad Sci U S A. 2007. PMID: 17494769 Free PMC article.
Bridging the gap between in vitro and in vivo models: a way forward to clinical translation of mitochondrial transplantation in acute disease states.
Bodenstein DF, Siebiger G, Zhao Y, Clasky AJ, Mukkala AN, Beroncal EL, Banh L, Aslostovar L, Brijbassi S, Hogan SE, McCully JD, Mehrabian M, Petersen TH, Robinson LA, Walker M, Zachos C; MITO2i-MbD Mitochondrial Transplant Consortium; Viswanathan S, Gu FX, Rotstein OD, Cypel M, Radisic M, Andreazza AC. Bodenstein DF, et al. Among authors: viswanathan s. Stem Cell Res Ther. 2024 May 31;15(1):157. doi: 10.1186/s13287-024-03771-8. Stem Cell Res Ther. 2024. PMID: 38816774 Free PMC article. Review.
Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing.
Malla R, Viswanathan S, Makena S, Kapoor S, Verma D, Raju AA, Dunna M, Muniraj N. Malla R, et al. Among authors: viswanathan s. Cancers (Basel). 2024 Apr 11;16(8):1463. doi: 10.3390/cancers16081463. Cancers (Basel). 2024. PMID: 38672545 Free PMC article. Review.
669 results